About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TELA Bio, Inc. - Common stock (NQ:TELA)

0.7348 +0.0148 (+2.06%)
Streaming Delayed Price Updated: 10:34 AM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TELA Bio, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) 
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery 
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Recap: TELA Bio Q4 Earnings ↗
 
Via Benzinga
News headline image
Preview: TELA Bio's Earnings ↗
 
Via Benzinga
News headline image
Recap: TELA Bio Q3 Earnings ↗
 
Via Benzinga
News headline image
Recap: TELA Bio Q1 Earnings ↗
 
Via Benzinga
News headline image
TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023 ↗
TELA stock results show that TELA Bio missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue 
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
TELA Bio to receive at least $8 million and up to $12 million in total consideration 
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 21, 2024 ↗
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
News headline image
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Take Part in Connecting the Dots
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
TELA Bio Reports Third Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Announce Third Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 9, 2023 ↗
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
News headline image
TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
New addition expands reconstruction options for surgeons and patients 
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Reports Second Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio to Participate in the Jefferies Global Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab
Company prioritizes education with a variety of in-person and virtual training programs 
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
TELA Bio Reports First Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 11, 2023 ↗
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.